Bruni J V & Co. Co. Invests $13.30 Million in IQVIA Holdings Inc. (NYSE:IQV)

Bruni J V & Co. Co. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 67,700 shares of the medical research company’s stock, valued at approximately $13,304,000. IQVIA comprises 1.5% of Bruni J V & Co. Co.’s investment portfolio, making the stock its 24th largest holding.

Several other large investors also recently modified their holdings of the stock. Private Trust Co. NA increased its stake in shares of IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after purchasing an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co grew its stake in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares in the last quarter. Howard Capital Management Inc. grew its stake in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after buying an additional 54 shares in the last quarter. Huntington National Bank grew its stake in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after buying an additional 56 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $188.89 on Friday. IQVIA Holdings Inc. has a 52-week low of $184.66 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $33.26 billion, a P/E ratio of 25.19, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a fifty day moving average of $199.13 and a 200-day moving average of $214.96.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.